The Latest Breaking News from FDA

Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 91% to $0.2530 after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced a price target of $6.50.

The Food and Drug Administration is determined to crack down on businesses that sell vaping products without its approval since e-cigarettes and e-liquids that contain nicotine have been considered a prescription-only medicine since 2021, reported STAT.

SACRAMENTO, Calif. — The wife of a Northern California congressman died late last year after ingesting a plant that is generally considered safe and is used as an herbal remedy for a variety of ailments, including diabetes, obesity and high cholesterol, KHN has learned.

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Mehmet Oz’s advocacy for the drug hydroxychloroquine in the early days of the COVID-19 pandemic is cited in a new congressional report that accuses former President Donald Trump’s administration of pressuring the Food and Drug Administration to endorse unproven treatments and vaccines.

Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults

The likelihood that the Supreme Court considers the FDA's treatment of vaping products is increasing.

Congressional investigation finds new evidence of efforts to override health decisions early in pandemic

Recently, the Federal Trade Commission (FTC) announced that it will send payments to 576 consumers across the country who purchased 'deceptively marketed' cannabidiol (CBD) products from Arizona-based Kushly Industries LLC.